Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.5K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.5K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

4.0K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.0K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

2.9K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.9K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.8K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Botulinum Toxin Type A (BoNT-A) Use for Post-Stroke Spasticity: A Multicenter Study Using Natural Language Processing and Machine Learning.

Toxins·2024
Same author

Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.

Bioorganic & medicinal chemistry letters·2014
Same author

Synergistic promotion of blood vessel regeneration by astragaloside IV and ferulic acid from electrospun fibrous mats.

Molecular pharmaceutics·2013
Same author

Effects of molecular structure of polyphenols on their noncovalent interactions with oat β-glucan.

Journal of agricultural and food chemistry·2013
Same author

Tuning donut profile for spatial resolution in stimulated emission depletion microscopy.

The Review of scientific instruments·2013
Same author

A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing.

Prenatal diagnosis·2013

Related Experiment Video

Updated: Feb 20, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K

Androstene-3,5-dienes as ER-beta selective SERMs.

Timothy A Blizzard1, Candido Gude, Jerry D Morgan

  • 1Merck Research Laboratories, Rahway, NJ 07065, USA. tim_blizzard@merck.com

Bioorganic & Medicinal Chemistry Letters
|September 25, 2007
PubMed
Summary

New androstene-3,5-diene derivatives show affinity for estrogen receptor-beta (ER-beta), even without the C-3 hydroxyl group. Diene 4 acts as a potent and selective ER-beta agonist, outperforming selectivity for the androgen receptor (AR).

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

6.8K

Related Experiment Videos

Last Updated: Feb 20, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.4K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

6.8K

Area of Science:

  • Medicinal Chemistry
  • Endocrinology
  • Molecular Pharmacology

Background:

  • Estrogen receptor (ER) activity has been traditionally linked to the C-3 hydroxyl group in steroid derivatives.
  • Understanding the structural requirements for ER modulation is crucial for developing targeted therapies.
  • The androgen receptor (AR) is another key steroid hormone receptor with implications in various physiological and pathological processes.

Purpose of the Study:

  • To synthesize and characterize novel androstene-3,5-diene derivatives.
  • To investigate the binding affinity and selectivity of these derivatives for estrogen receptor-beta (ER-beta).
  • To evaluate their potential as ER-beta agonists or antagonists, particularly in the absence of the C-3 hydroxyl group.

Main Methods:

  • Chemical synthesis of a series of androstene-3,5-diene derivatives.
  • In vitro assays to determine binding affinity for ER-beta.
  • Selectivity assays comparing ER-beta and androgen receptor (AR) binding.
  • Functional assays to assess ER-beta agonist/antagonist activity.

Main Results:

  • Several androstene-3,5-diene derivatives were successfully prepared.
  • Some analogs demonstrated significant affinity for ER-beta, despite lacking the C-3 hydroxyl group.
  • Diene 4 exhibited potent and selective ER-beta agonistic activity.
  • Diene 4 showed higher selectivity for ER-beta compared to the androgen receptor (AR).

Conclusions:

  • The C-3 hydroxyl group is not essential for ER-beta binding and activity in androstene-3,5-diene derivatives.
  • Novel androstene-3,5-diene analogs can be developed as selective ER-beta modulators.
  • Diene 4 represents a promising lead compound for further investigation as a selective ER-beta agonist with potential therapeutic applications.